Junmei Peng

Hengyang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Corrigendum to "Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity" [Eur. J. Med. Chem. 279 (2024) 116838].

Corrigendum to "Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity" [Eur. J. Med. Chem. 279 (2024) 116838].

Journal: European journal of medicinal chemistry

Published: November 27, 2024

Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity.

Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity.

Journal: European journal of medicinal chemistry

Published: June 21, 2024

High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.

High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.

Journal: European journal of medicinal chemistry

Published: February 17, 2024

The role of stromal cells in epithelial-mesenchymal plasticity and its therapeutic potential.

The role of stromal cells in epithelial-mesenchymal plasticity and its therapeutic potential.

Journal: Discover oncology

Published: June 11, 2023

The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia.

The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia.

Journal: Mini reviews in medicinal chemistry

Published: January 09, 2023

Design, synthesis, and evaluation of 1H-benzo[d]imidazole-4-carboxamide PARP-1 inhibitors using different saturated nitrogen-contained heterocycle as linker group.

Design, synthesis, and evaluation of 1H-benzo[d]imidazole-4-carboxamide PARP-1 inhibitors using different saturated nitrogen-contained heterocycle as linker group.

Journal: Chemical biology & drug design

Published: November 04, 2022

Applications of "linkers" in fragment-based drug design.

Applications of "linkers" in fragment-based drug design.

Journal: Bioorganic chemistry

Published: March 09, 2022

Withdrawal: Advances in Development of Drugs for Chronic Myelogenous Leukemia

Withdrawal: Advances in Development of Drugs for Chronic Myelogenous Leukemia

Journal: Mini reviews in medicinal chemistry

Published: November 23, 2021

Recent Progress in the Research on Benzimidazole PARP-1 Inhibitors.

Recent Progress in the Research on Benzimidazole PARP-1 Inhibitors.

Journal: Mini reviews in medicinal chemistry

Published: November 16, 2021

Recent progress of research on anti-tumor agents using benzimidazole as the structure unit.

Recent progress of research on anti-tumor agents using benzimidazole as the structure unit.

Journal: Chemical biology & drug design

Published: November 04, 2021

Synthesis and evaluation of 2-(4-[4-acetylpiperazine-1-carbonyl] phenyl)-1H-benzo[d]imidazole-4-carboxamide derivatives as potential PARP-1 inhibitors and preliminary study on structure-activity relationship.

Synthesis and evaluation of 2-(4-[4-acetylpiperazine-1-carbonyl] phenyl)-1H-benzo[d]imidazole-4-carboxamide derivatives as potential PARP-1 inhibitors and preliminary study on structure-activity relationship.

Journal: Drug development research

Published: April 20, 2021

Anti-chronic myeloid leukemia activity and quantitative structure-activity relationship of novel thiazole aminobenzamide derivatives.

Anti-chronic myeloid leukemia activity and quantitative structure-activity relationship of novel thiazole aminobenzamide derivatives.

Journal: Bioorganic & medicinal chemistry letters

Published: February 04, 2021

Showing 1-12 of 19

Last Updated: 09/26/2026